Graves Ophthalmopathy Terminated Phase 2 Trials for Otelixizumab (DB05496)

Also known as: Graves ophthalmopathy / Ophthalmopathy, Graves / Thyroid eye disease / Graves' ophthalmopathy / Endocrine ophthalmopathy

IndicationStatusPhase
DBCOND0000969 (Graves Ophthalmopathy)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01114503A Safety and Tolerability Study of Otelixizumab in Thyroid Eye DiseaseTreatment